AbbVie will utilize its Oxford site to enhance research and development efforts focused on treatments for immunological, neurological, and oncological diseases. This strategic move is part of AbbVie’s broader initiative to strengthen its presence in the UK and advance its pipeline in these critical therapeutic areas.
This expansion could signify increased investment in the UK biotech landscape, potentially benefiting local suppliers and research institutions. It may also enhance AbbVie’s ability to innovate and bring new therapies to market, which could impact competition in the immunology and oncology sectors.
Source: pharmaceutical-technology.com · Image: US Naval Research Laboratory in 2001 by U. S. Naval Research Laboratory, Public domain, via Wikimedia Commons
Open the full market picture for your next decision →
